Covered recipient · General Payments record
ERICA ROSE COHEN
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$116,111.53
195 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $91,206.50 | 34 |
| Consulting Fee | $10,233.50 | 5 |
| Travel and Lodging | $9,387.85 | 22 |
| Food and Beverage | $5,187.68 | 126 |
| Education | $96.00 | 8 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $52,872.11 | 44 |
| ABBVIE INC. | $33,676.50 | 52 |
| PFIZER INC. | $14,784.48 | 33 |
| Takeda Pharmaceuticals U.S.A., Inc. | $7,406.27 | 13 |
| Lilly USA, LLC | $6,045.80 | 8 |
| Celltrion USA Inc. | $272.79 | 13 |
| Janssen Scientific Affairs, LLC | $238.24 | 3 |
| Regeneron Healthcare Solutions, Inc. | $163.12 | 3 |
| Celgene Corporation | $117.87 | 6 |
| QOL Medical, LLC | $89.19 | 3 |
| AIMMUNE THERAPEUTICS, INC. | $81.37 | 1 |
| Daiichi Sankyo Inc. | $77.31 | 3 |
| Fresenius Kabi USA, LLC | $64.92 | 3 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $59.23 | 3 |
| Sandoz Inc. | $53.43 | 2 |
| IRONWOOD PHARMACEUTICALS, INC | $35.93 | 2 |
| Intercept Pharmaceuticals, Inc. | $24.98 | 1 |
| Exact Sciences Corporation | $24.86 | 1 |
| Ardelyx, Inc. | $23.13 | 1 |
Page 2 of 4; records 51–100 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ERICA ROSE COHEN
NPI 1750672499 · CMS profile ID 4222116
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
CHEVY CHASE, MD
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1750672499?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ERICA ROSE COHEN, NPI 1750672499, CMS profile ID 4222116. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750672499?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). ERICA ROSE COHEN, NPI 1750672499, CMS profile ID 4222116. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750672499?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- ERICA ROSE COHEN, NPI 1750672499, CMS profile ID 4222116, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 195 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1750672499?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
195 matching records · $116,111.53 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 195.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $25.72 | 10/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078716800 | CMS |
| Janssen Biotech, Inc. | $3,375.00 | 10/12/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078716174 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $24.11 | 10/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137516076 | CMS |
| Janssen Biotech, Inc. | $114.55 | 10/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078717235 | CMS |
| Celltrion USA Inc. | $13.93 | 10/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1075850073 | CMS |
| Celltrion USA Inc. | $0.66 | 10/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1075850075 | CMS |
| Janssen Biotech, Inc. | $1,500.00 | 10/05/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078717172 | CMS |
| Janssen Biotech, Inc. | $38.15 | 09/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078716398 | CMS |
| Janssen Biotech, Inc. | $59.33 | 09/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078716518 | CMS |
| Janssen Biotech, Inc. | $38.93 | 09/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078717191 | CMS |
| Daiichi Sankyo Inc. | $29.10 | 09/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089410040 | CMS |
| Janssen Biotech, Inc. | $451.89 | 09/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078716454 | CMS |
| Janssen Biotech, Inc. | $149.87 | 09/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078716603 | CMS |
| Janssen Biotech, Inc. | $318.31 | 09/27/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078716992 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $19.83 | 09/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137516073 | CMS |
| ABBVIE INC. | $5.08 | 09/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103485851 | CMS |
| ABBVIE INC. | $22.41 | 09/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103485853 | CMS |
| ABBVIE INC. | $134.58 | 09/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103485855 | CMS |
| ABBVIE INC. | $577.80 | 09/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104181412 | CMS |
| Janssen Biotech, Inc. | $14.77 | 09/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078716426 | CMS |
| Celltrion USA Inc. | $23.26 | 09/23/2024 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1075850071 | CMS |
| Celgene Corporation | $24.68 | 09/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101162708 | CMS |
| PFIZER INC. | $25.05 | 09/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130959979 | CMS |
| ABBVIE INC. | $22.72 | 09/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103485849 | CMS |
| Lilly USA, LLC | $937.50 | 09/13/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1134968049 | CMS |
| Fresenius Kabi USA, LLC | $24.62 | 09/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146959003 | CMS |
| Lilly USA, LLC | $3,750.00 | 08/28/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136172690 | CMS |
| ABBVIE INC. | $16.84 | 08/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103485847 | CMS |
| PFIZER INC. | $13.19 | 08/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130938152 | CMS |
| ABBVIE INC. | $2,025.00 | 08/15/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103132997 | CMS |
| ABBVIE INC. | $337.50 | 08/15/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103132999 | CMS |
| Celgene Corporation | $21.36 | 08/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101162706 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.48 | 08/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137516069 | CMS |
| ABBVIE INC. | $4,725.00 | 08/07/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103145865 | CMS |
| ABBVIE INC. | $4,725.00 | 08/07/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103145867 | CMS |
| Daiichi Sankyo Inc. | $29.62 | 08/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089410120 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $23.31 | 08/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137516065 | CMS |
| Janssen Biotech, Inc. | $19.22 | 07/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078716514 | CMS |
| PFIZER INC. | $1,012.50 | 07/30/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1130976810 | CMS |
| ABBVIE INC. | $60.00 | 07/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103485831 | CMS |
| ABBVIE INC. | $25.00 | 07/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103485833 | CMS |
| ABBVIE INC. | $70.00 | 07/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103485835 | CMS |
| ABBVIE INC. | $25.00 | 07/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103485837 | CMS |
| ABBVIE INC. | $60.00 | 07/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103485839 | CMS |
| ABBVIE INC. | $25.00 | 07/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103485841 | CMS |
| ABBVIE INC. | $70.00 | 07/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103485843 | CMS |
| ABBVIE INC. | $25.00 | 07/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103485845 | CMS |
| ABBVIE INC. | $171.72 | 07/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104181396 | CMS |
| ABBVIE INC. | $48.55 | 07/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104181398 | CMS |
| ABBVIE INC. | $198.08 | 07/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104181400 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $3,530.00 | 2 |
| PY2025 | Principal investigator | $288,203.76 | 50 |
| PY2024 | Recipient | $17.50 | 1 |
| PY2024 | Principal investigator | $260,018.32 | 49 |
| PY2023 | Recipient | $2,510.93 | 1 |
| PY2023 | Principal investigator | $72,690.91 | 31 |
| PY2022 | Recipient | $963.00 | 2 |
| PY2022 | Principal investigator | $96,273.90 | 23 |
| PY2021 | Recipient | $4,557.09 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
52 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,880.00 | 12/22/2025 | Non-covered Recipient Entity TOPOGRAPHY HEALTH INC | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223290074 |
| Principal investigator 1 | ABBVIE INC. | $6,253.61 | 12/04/2025 | Non-covered Recipient Entity TOPOGRAPHY HEALTH INC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202528534 |
| Recipient | PFIZER INC. | $3,200.00 | 11/25/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228726408 |
| Principal investigator 1 | ABBVIE INC. | $10,328.18 | 11/05/2025 | Non-covered Recipient Entity MGG GROUP CO INC DBA CHEVY CHASE CLINICAL RESEARCH | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202523043 |
| Principal investigator 1 | ABBVIE INC. | $28,834.75 | 10/09/2025 | Non-covered Recipient Entity MGG GROUP CO INC DBA CHEVY CHASE CLINICAL RESEARCH | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202515977 |
| Principal investigator 1 | PFIZER INC. | $100.00 | 09/25/2025 | Non-covered Recipient Entity Topography Health Inc | A MULTICENTER PROSPECTIVE NONINTERVENTIONAL STUDY OF REALWORLD EFFECTIVENESS OF ETRASIMOD IN PATIENTS WITH ULCERATIVE COLITIS ENDEAVOURUC | No dispute reported | 06/30/2026 | 1228742809 |
| Principal investigator 1 | PFIZER INC. | $900.00 | 09/08/2025 | Non-covered Recipient Entity Metropolitan Gastroenterology Group PC Chevy Chase Clinical Research | A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228755336 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,550.00 | 09/04/2025 | Non-covered Recipient Entity TOPOGRAPHY HEALTH INC | CD P3: Double-Blind Induction | No dispute reported | 06/30/2026 | 1211673071 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $11,396.00 | 09/04/2025 | Non-covered Recipient Entity TOPOGRAPHY HEALTH INC | CD P3: Double-Blind Induction | No dispute reported | 06/30/2026 | 1211673081 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,743.00 | 09/04/2025 | Non-covered Recipient Entity TOPOGRAPHY HEALTH INC | CD P3: Double-Blind Induction | No dispute reported | 06/30/2026 | 1211673089 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $15,810.00 | 09/04/2025 | Non-covered Recipient Entity TOPOGRAPHY HEALTH INC | CD P3: Double-Blind Induction | No dispute reported | 06/30/2026 | 1211673092 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25.00 | 08/28/2025 | Non-covered Recipient Entity Mgg Group Co. Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175227875 |
| Principal investigator 1 | Janssen Research & Development, LLC | $450.00 | 08/28/2025 | Non-covered Recipient Entity Mgg Group Co. Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175227894 |
| Principal investigator 1 | Janssen Research & Development, LLC | $541.00 | 08/28/2025 | Non-covered Recipient Entity Mgg Group Co. Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175227968 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,453.00 | 08/28/2025 | Non-covered Recipient Entity Mgg Group Co. Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175227993 |
| Principal investigator 1 | PFIZER INC. | $9,782.82 | 08/27/2025 | Non-covered Recipient Entity Topography Health Inc | A MULTICENTER PROSPECTIVE NONINTERVENTIONAL STUDY OF REALWORLD EFFECTIVENESS OF ETRASIMOD IN PATIENTS WITH ULCERATIVE COLITIS ENDEAVOURUC | No dispute reported | 06/30/2026 | 1228754189 |
| Principal investigator 1 | Eli Lilly and Company | $1,014.88 | 08/07/2025 | Non-covered Recipient Entity CHILDRENS CENTER FOR DIGESTIVE HEALTH CARE LLC | A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187878845 |
| Principal investigator 1 | Eli Lilly and Company | $273.88 | 08/07/2025 | Non-covered Recipient Entity CHILDRENS CENTER FOR DIGESTIVE HEALTH CARE LLC | A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE AND OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187879061 |
| Principal investigator 1 | ABBVIE INC. | $11,745.00 | 08/06/2025 | Non-covered Recipient Entity MGG GROUP CO INC DBA CHEVY CHASE CLINICAL RESEARCH | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202503023 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500.00 | 07/16/2025 | Non-covered Recipient Entity TOPOGRAPHY HEALTH INC | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223282646 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,000.00 | 07/16/2025 | Non-covered Recipient Entity TOPOGRAPHY HEALTH INC | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting (PANORAMA) | No dispute reported | 06/30/2026 | 1223282666 |
| Principal investigator 1 | ABBVIE INC. | $12,192.80 | 07/08/2025 | Non-covered Recipient Entity MGG GROUP CO INC DBA CHEVY CHASE CLINICAL RESEARCH | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202497500 |
| Principal investigator 1 | ABBVIE INC. | $4,290.00 | 07/02/2025 | Non-covered Recipient Entity MGG GROUP CO INC DBA CHEVY CHASE CLINICAL RESEARCH | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202496691 |
| Principal investigator 1 | Eli Lilly and Company | $246.15 | 06/24/2025 | Non-covered Recipient Entity CHILDRENS CENTER FOR DIGESTIVE HEALTH CARE LLC | A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE | No dispute reported | 06/30/2026 | 1187875385 |
| Principal investigator 1 | PFIZER INC. | $100.00 | 06/05/2025 | Non-covered Recipient Entity Topography Health Inc | A MULTICENTER PROSPECTIVE NONINTERVENTIONAL STUDY OF REALWORLD EFFECTIVENESS OF ETRASIMOD IN PATIENTS WITH ULCERATIVE COLITIS ENDEAVOURUC | No dispute reported | 06/30/2026 | 1228775269 |
| Principal investigator 1 | PFIZER INC. | $7,000.00 | 05/22/2025 | Non-covered Recipient Entity Topography Health Inc | A MULTICENTER PROSPECTIVE NONINTERVENTIONAL STUDY OF REALWORLD EFFECTIVENESS OF ETRASIMOD IN PATIENTS WITH ULCERATIVE COLITIS ENDEAVOURUC | No dispute reported | 06/30/2026 | 1228776606 |
| Principal investigator 1 | ABBVIE INC. | $4,040.00 | 05/07/2025 | Non-covered Recipient Entity MGG GROUP CO INC DBA CHEVY CHASE CLINICAL RESEARCH | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202484131 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,009.00 | 04/28/2025 | Non-covered Recipient Entity Topography Hlth Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175172636 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,850.00 | 04/28/2025 | Non-covered Recipient Entity Topography Hlth Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175172873 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 04/28/2025 | Non-covered Recipient Entity Topography Hlth Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175173264 |
| Recipient | PFIZER INC. | $330.00 | 04/24/2025 | Covered Recipient Physician | ETRASIMOD CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228769173 |
| Principal investigator 1 | PFIZER INC. | $61.00 | 03/19/2025 | Non-covered Recipient Entity Metropolitan Gastroenterology Group PC Chevy Chase Clinical Research | A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228719527 |
| Principal investigator 1 | PFIZER INC. | $768.00 | 03/19/2025 | Non-covered Recipient Entity Metropolitan Gastroenterology Group PC Chevy Chase Clinical Research | A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228774907 |
| Principal investigator 1 | PFIZER INC. | $2,716.30 | 03/19/2025 | Non-covered Recipient Entity Metropolitan Gastroenterology Group PC Chevy Chase Clinical Research | A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228775707 |
| Principal investigator 1 | PFIZER INC. | $203.00 | 03/19/2025 | Non-covered Recipient Entity Metropolitan Gastroenterology Group PC Chevy Chase Clinical Research | A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228775726 |
| Principal investigator 1 | PFIZER INC. | $101.00 | 03/19/2025 | Non-covered Recipient Entity Metropolitan Gastroenterology Group PC Chevy Chase Clinical Research | A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1228776960 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $54,423.00 | 02/07/2025 | Non-covered Recipient Entity Topography Health Inc | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice | No dispute reported | 06/30/2026 | 1235992913 |
| Principal investigator 1 | Eli Lilly and Company | $12,409.00 | 01/28/2025 | Non-covered Recipient Entity MGG GROUP CORP INC | A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE | No dispute reported | 06/30/2026 | 1187886750 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $109.17 | 01/27/2025 | Non-covered Recipient Entity Chevy Chase Clinical Research | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice | No dispute reported | 06/30/2026 | 1235998166 |
| Principal investigator 1 | PFIZER INC. | $1,054.32 | 01/16/2025 | Non-covered Recipient Entity Topography Health Inc | A MULTICENTER PROSPECTIVE NONINTERVENTIONAL STUDY OF REALWORLD EFFECTIVENESS OF ETRASIMOD IN PATIENTS WITH ULCERATIVE COLITIS ENDEAVOURUC | No dispute reported | 06/30/2026 | 1228765883 |
| Principal investigator 1 | Eli Lilly and Company | $48,113.90 | 01/10/2025 | Non-covered Recipient Entity MGG GROUP CORP INC | A MULTICENTER, PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB | No dispute reported | 06/30/2026 | 1187884950 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 01/02/2025 | Non-covered Recipient Entity Mgg Group Co. Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175227886 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 01/02/2025 | Non-covered Recipient Entity Mgg Group Co. Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175227901 |
| Principal investigator 1 | Janssen Research & Development, LLC | $484.00 | 01/02/2025 | Non-covered Recipient Entity Mgg Group Co. Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175227907 |
| Principal investigator 1 | Janssen Research & Development, LLC | $242.00 | 01/02/2025 | Non-covered Recipient Entity Mgg Group Co. Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175227913 |
| Principal investigator 1 | Janssen Research & Development, LLC | $450.00 | 01/02/2025 | Non-covered Recipient Entity Mgg Group Co. Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175227923 |
| Principal investigator 1 | Janssen Research & Development, LLC | $242.00 | 01/02/2025 | Non-covered Recipient Entity Mgg Group Co. Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175227931 |
| Principal investigator 1 | Janssen Research & Development, LLC | $450.00 | 01/02/2025 | Non-covered Recipient Entity Mgg Group Co. Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175227943 |
| Principal investigator 1 | Janssen Research & Development, LLC | $242.00 | 01/02/2025 | Non-covered Recipient Entity Mgg Group Co. Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175227949 |
| Principal investigator 1 | Janssen Research & Development, LLC | $242.00 | 01/02/2025 | Non-covered Recipient Entity Mgg Group Co. Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175227957 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 01/02/2025 | Non-covered Recipient Entity Mgg Group Co. Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175227976 |
| Principal investigator 1 | Janssen Research & Development, LLC | $541.00 | 01/02/2025 | Non-covered Recipient Entity Mgg Group Co. Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175227984 |